The initial success of Viagra undeniably transformed the drug landscape, but placing funds in companies strongly reliant on generic versions presents a challenging picture. While early earnings were significant, the expiration of patents and the rise of cheaper alternatives have weakened sales. Consequently, a thorough evaluation of current revenue